Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
Inhibrx Biosciences, Inc
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
Emory University
Wake Forest University Health Sciences
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Emory University
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
Brigham and Women's Hospital
National Cancer Institute (NCI)
Lithuanian University of Health Sciences
University of California, San Diego
M.D. Anderson Cancer Center
University Hospital, Strasbourg, France
Medical University of South Carolina
H. Lee Moffitt Cancer Center and Research Institute
Sir Mortimer B. Davis - Jewish General Hospital
University of Texas Southwestern Medical Center
Cancer Research UK
Mansoura University
Insel Gruppe AG, University Hospital Bern
Centre Leon Berard
University of Connecticut
Emory University
Sanford Health
Insel Gruppe AG, University Hospital Bern
University Medical Center Groningen
Erasmus Medical Center
Başakşehir Çam & Sakura City Hospital
Thomas Jefferson University
Washington University School of Medicine
Fudan University